Abstracts tagged "Administrative Data"

Abstract Number: 0490 • ACR Convergence 2024
Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Hip or pelvis fractures (HOP) are common osteoporotic fractures (OP) with significant risks of medical complications, placement into care, reduced quality of life and…
Abstract Number: 1717 • ACR Convergence 2024
Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Md Rashedul Hoque¹, Diane Lacaille², J. Antonio Avina-Zubieta², Mary A. De Vera³, Yi Qian⁴, John Esdaile⁵ and Hui Xie⁶, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, Canada, ⁵Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and hospitalization costs among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods: We…
Abstract Number: 2622 • ACR Convergence 2024
Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring
Emily Smitherman¹, Justin Leach¹, Aimee Hersh², Melissa Mannion¹, Jinoos Yazdany³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³UCSF, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Poorly controlled childhood-onset lupus nephritis (cLN) can lead to end-stage kidney disease (ESKD), requiring kidney replacement therapies with substantial financial and quality of life…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
Abstract Number: 1720 • ACR Convergence 2024
Herpes Zoster Risk Following Initiation of Immunosuppressive Therapy Among Adults with Rheumatic Disease
Justin Gatwood¹, Yong Zhu², Andrea Steffens², Stephanie Gallagher², Mary DuCharme² and Nikita Stempniewicz¹, ¹GSK, Philadelphia, PA, ²Optum Life Sciences, Eden Prairie, MN
Background/Purpose: Previous studies have demonstrated that the risk of herpes zoster (HZ) among adults with rheumatic disease, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA),…
Abstract Number: 2673 • ACR Convergence 2024
Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Diane Lacaille¹, Coraline Danieli², Kasra Moolooghy¹ and Michal Abrahamowicz³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, ³McGill University, Verdun, Canada
Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
Abstract Number: 0564 • ACR Convergence 2024
The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
Mayas Arraf¹, Devy Zisman², walid Saliba³, Nili Stein⁴ and Joy Feld⁵, ¹Technion medical school, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel medical center, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
Abstract Number: 1722 • ACR Convergence 2024
Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases
Pradip Moon¹, Weizi Li¹, Antoni Chan² and Eghosa Bazuaye², ¹University of Reading, Reading, United Kingdom, ²Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Rheumatic and musculoskeletal diseases (RMD) affect up to one-third of the UK population and are the number one cause of disability and one of…
Abstract Number: 2674 • ACR Convergence 2024
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
christina Charles-Schoeman¹, Patrick Zueger², Erin Blondell², Siran Fang², Yi Peng², Manish Jain³ and John Tesser⁴, ¹UCLA Medical Center, Santa Monica, CA, ²AbbVie Inc, North Chicago, IL, ³Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, ⁴Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…
Abstract Number: 0709 • ACR Convergence 2024
Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records
Yiming Luo, Gongbo Zhang, Chunhua Weng and Elana Bernstein, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune rheumatic disease. International Classification of Diseases (ICD) code counts (for example, using ≥ 2 ICD-10 codes…
Abstract Number: 1728 • ACR Convergence 2024
Higher Oral Steroid Dose Is Associated with Worse Survival in Immune Checkpoint Inhibitor-Treated Rheumatoid Arthritis Patients with Metastatic Non-Small Cell Lung Cancer
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²The University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: It is unknown if steroid use for RA patients could interfere with the benefits of immune checkpoint inhibitors (ICI) as cancer therapies. Additionally, it…
Abstract Number: 0723 • ACR Convergence 2024
Sociodemographic Factors Associated with Clinic Non-attendance and Unscheduled Emergency Care Episodes in ANCA-associated Vasculitis
Warren RG James¹, Corri Black¹, Neil Basu², Mark A Little³ and Rosemary Hollick¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of Glasgow, Glasgow, Scotland, United Kingdom, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Increasing evidence suggests that socioeconomic status drives differences in outcomes for people with rheumatic conditions. Individuals with complex, rare rheumatic conditions such as antineutrophil…
Abstract Number: 1868 • ACR Convergence 2024
Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis
Berk Degirmenci¹, Christine Peloquin², Sara Lodi¹, Pedro M Machado³, S. Reza Jafarzadeh², Tuhina Neogi², Lianne S Gensler⁴, Maureen Dubreuil⁵ and Jean Liew², ¹Boston University, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁴Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Current axial spondyloarthritis (axSpA) guidelines do not provide recommendations for opioids in pain management. Opioid use is common in axSpA, despite widespread uptake of…
Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St-Pierre⁴, Olga Basso¹, Anick Bérard⁵ and Evelyne Vinet³, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…
Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Nicoleta Petrica¹, Nathan Cohen¹, Maria Pini¹, Minjee Park², Mathieu Rosé³ and Jean-Francois Ricci², ¹Alira Health, Paris, France, ²Alira Health, Basel, Switzerland, ³Alira Health, Barcelone, Spain
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…

1
2
3
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].